Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
454 Results for "
ALK
" in MedChemExpress (MCE) Product Catalog:
Products (454)
454 Results for "ALK" in MCE Product Catalog:
Cat. No.: HY-15656R
CAS No.: 1032900-25-6
Synonyms: LDK378 (Standard)
Research Areas:
Ceritinib (Standard) is the analytical standard of Ceritinib (HY-15656). This product is intended for research and analytical applications. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .
Cat. No.: HY-16590R
CAS No.: 1365267-27-1
Research Areas:
X-376 (Standard) is the analytical standard of X-376. This product is intended for research and analytical applications. X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC50=0.61 nM). X-376 is a less potent inhibitor of MET (IC50=0.69 nM). X-376 displays potent anti-tumor activity .
Cat. No.: HY-144423
CAS No.: 2700265-61-6
Target:
Research Areas:
Trk-IN-10 (Compound 14j) is a potent inhibitor of TRK (IC50 = 0.86, 6.92 nM, against TrkA, TrkA G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity .
Cat. No.: HY-15656AR
CAS No.: 1380575-43-8
Synonyms: LDK378 dihydrochloride (Standard)
Research Areas:
Ceritinib (LDK378) dihydrochloride (Standard) is the analytical standard of Ceritinib dihydrochloride (HY-15656A). This product is intended for research and analytical applications. Ceritinib dihydrochloride is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib dihydrochloride also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .
Cat. No.: HY-12678R
CAS No.: 1108743-60-7
Synonyms: NMS-E628 (Standard); RXDX-101 (Standard)
Research Areas:
Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
Cat. No.: HY-N4107R
CAS No.: 10351-88-9
Target:
Cat. No.: HY-103022R
CAS No.: 1802220-02-5
Synonyms: TPX-0005 (Standard); Ropotrectinib (Standard)
Research Areas:
Repotrectinib (Standard) is the analytical standard of Repotrectinib (HY-103022). This product is intended for research and analytical applications. Repotrectinib (TPX-0005) is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib has anti-cancer activity .
Target:
Research Areas:
HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .
Cat. No.: HY-16769
CAS No.: 1356033-60-7
Synonyms: P7170; AK151761
Panulisib (P7170; AK151761) is an orally active inhibitor of PI3K (IC50 = 2.2 nM) and mTOR (IC50 = 4.4 nM). Panulisib inhibits ALK1 and DNA-PK, two enzymes that respectively participate in angiogenesis and DNA repair, with IC50 values of 47 nM and 1.5 nM respectively. Panulisib inhibits cell proliferation and apoptosis. Panulisib can be used for research on breast cancer and non-small cell lung cancer .
Cat. No.: HY-111277
CAS No.: 856693-04-4
Research Areas:
CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma .
Cat. No.: HY-120387
CAS No.: 1253286-90-6
Research Areas:
SMU-B is the orally active inhibitor for ALK (IC50<0.5 nM), c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models .
Research Areas:
MY10 is a potent and orally active receptor protein tyrosine phosphatase (RPTPβ/ζ) inhibitor. MY10 reduces NF-κB p65 expression. MY10 activates tyrosine phosphorylation of c-Met. MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression. MY10 attenuates binge-like ethanol consumption and ethanol reward. MY10 can be used in the study of neurological and vascular diseases .
Research Areas:
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .
Cat. No.: HY-184863
CAS No.: 1034617-66-7
Target:
Research Areas:
PLK1-IN-17 is a potent PLK1 inhibitor with an IC50 of 2 nM. PLK1-IN-17 shows high selectivity for PLK2 and CDK2/A, moderate selectivity for PLK3, only weak activity against CK2, FLT3 and NEK6, and no activity against PDGFR, ALK and another 37 kinases. PLK1-IN-17 inhibits the proliferation of ovarian cancer cells and can be used in ovarian cancer-related research .
Cat. No.: HY-W814315
CAS No.: 1256577-71-5
Synonyms: CH5424802 analog; RO5424802 analog; RG7853 analog
Target:
Research Areas:
Alectinib analog (CH5424802 analog) is a selective ALK inhibitor with activity in blocking resistance gating mutations. The synthetic optimization of alectinib analog allows it to be combined with specific peptides to improve the ability to target cancer cells. Alectinib analog exhibits low micromolar IC50 values in antiproliferation and shows good cytotoxic effects. The inhibitory activity of alectinib analog is closely related to its stability and release of active ingredients. Alectinib analog demonstrated the ability to inhibit vascular septal length or width in an in vivo zebrafish model .
Cat. No.: HY-12678S
Synonyms: NMS-E628-d4; RXDX-101-d4
Target:
Ack1 JAK Anaplastic lymphoma kinase (ALK) Src Bcr-Abl Checkpoint Kinase (Chk) FGFR ROS Kinase
Research Areas:
(R)-9b is an ATP-competitive kinase inhibitor. (R)-9b binds to the ATP-binding site of ACK1/TNK2, inhibiting their kinase activity and autophosphorylation, with a human IC50 of 56 nM. (R)-9b also inhibits JAK2, Tyk2, ALK, c-Src, ABL1, CHK1, FGFR1, LCK, and ROS/ROS1. (R)-9b can be used for research on prostate cancer .
Cat. No.: HY-P72453
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFBR1; Serine/Threonine-Protein Kinase Receptor R4; Prev. ESS1; Activin Receptor-Like Kinase 5; Prev. MSSE; TbetaR-I; ALK-5; TGFR-1; ALK5; SKR4; Transforming Growth Factor-Beta Receptor Type I; Multiple Self-Healing Squamous Epithelioma; TGF-Beta Receptor Type-1; TGF-Beta Type I Receptor; ACVRLK4; TGF-Beta Receptor Type I; TBR-I; LDS1A; TBRI; LDS2A; Activin A Receptor Type II-Like Protein Kinase Of 53kD; AAT5; Mutant Transforming Growth Factor Beta Receptor I; LDS1; Activin A Receptor Type II-Like Kinase, 53kDa; Transforming Growth Factor Beta Receptor 1; Transforming Growth Factor Beta Receptor I
Species:
Human
Source:
HEK293
Cat. No.: HY-P706225
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TGFBR1; Serine/Threonine-Protein Kinase Receptor R4; Prev. ESS1; Activin Receptor-Like Kinase 5; Prev. MSSE; TbetaR-I; ALK-5; TGFR-1; ALK5; SKR4; Transforming Growth Factor-Beta Receptor Type I; Multiple Self-Healing Squamous Epithelioma; TGF-Beta Receptor Type-1; TGF-Beta Type I Receptor; ACVRLK4; TGF-Beta Receptor Type I; TBR-I; LDS1A; TBRI; LDS2A; Activin A Receptor Type II-Like Protein Kinase Of 53kD; AAT5; Mutant Transforming Growth Factor Beta Receptor I; LDS1; Activin A Receptor Type II-Like Kinase, 53kDa; Transforming Growth Factor Beta Receptor 1; Transforming Growth Factor Beta Receptor I
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
